From 28 June till 1 July 2023: HIGHLIGHTS ON GASTROINTESTINAL CANCER
Your direct line with Barcelona
The World Congress on Gastrointestinal Cancer 2023 brings together leading experts in the field of gastroinestinal cancer from around the world. And, as usual, they gather together in Barelona, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of
Daily highlights
In this highlight video, we are fortunate to have Dr Francesco Sclafani sharing the highlights. Dr Sclafani will delve into a range of compelling topics surrounding colorectal cancer, which were thoughtfully presented during the session held on Saturday.
Dr. Sclafani
Dr Jochen Decaestecker focuses in this highlight video on key advancements and noteworthy developments in the field of hepatocellular cancer.
Dr Decaestecker initially discusses the presentation delivered by Prof. Jessica Zucman-Rossi from Université Paris Cité. She provided valuable insights into
Dr Vandamme’s discussion revolves around two important topics. Firstly, he highlights the use of ctDNA (circulating tumour DNA) as a tool for guiding treatment decisions in colorectal cancer. Secondly, Dr Vandamme focuses on mutational signatures and the role of Homologous
Dr Eduard Callebout, working at UZ Gent, highlights key presentations from the session on oesophageal and stomach cancers at the 25th World Congress on Gastrointestinal Cancer in Barcelona. His video provides valuable insights into the latest developments in the field.
Dr Willem Lybaert brings us the daily highlights on pancreatic and biliary cancer. He delves into four notable studies, two of which focus on pancreatic cancer.
The first study, known as the NAPOLI 3 STUDY, compares the efficacy of
In-depth stories
During the interview, Professor Dr. Zev Wainberg from the University of California, Los Angeles, presents additional results from the phase 3 NAPOLI-3 TRIAL. The trial aimed to compare the efficacy of NALIRIFOX (liposomal irinotecan + 5-FU + LV + oxaliplatin)
The SUNLIGHT study holds significant importance in the field of colorectal cancer, specifically in the third-line treatment setting. It is the first study to compare two active regimens in this particular context. The study investigated the addition of bevacizumab to
Prof. Dr Jeroen Dekervel, Prof. Dr André D’Hoore, and Prof. Dr Karen Haustermans bring their individual perspectives to the discussion on total neoadjuvant treatment for locally advanced rectal cancer.
Prof Dr Bruno Sangro presents the updated Phase III HIMALAYA study analysis. The study evaluated the efficacy and safety of the STRIDE regimen, consisting of a single priming dose of tremelimumab plus durvalumab, compared to sorafenib in patients with unresectable
Prof Dr Zev Wainberg presents the final analysis of the FIGHT Trial. This significant study investigated the efficacy of bemarituzumab, a monoclonal antibody that selectively inhibits FGFR2b signalling and enhances antibody-dependent cellular toxicity against tumour cells expressing FGFR2b. The trial
Poster selection
Julie Geerts from the Erasmus MC Cancer Institute in Rotterdam on a comparison between anthracyclines triplets versus FLOP as perioperative chemotherapy for operable gastro-esophageal or gastric cancer.
Charlène van der Zijden from the Erasmus MC Cancer Institute in Rotterdam on induction chemotherapy followed by restaging after surgery for advanced esophageal cancer.
Joshua Tobias, affiliated with the Medical University of Vienna, on the PD-8 HERIZON. A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer.
Sven Van Laere from the UZ Brussel on the total neoadjuvant treatment of rectal cancer by MRI-guided radiotherapy.